Advertisement

Gender Bias in Studies for FDA Premarket Approval of Cardiovascular Devices

  • Sanket S. Dhruva
  • Esme B. Cullen
  • Rita F. RedbergEmail author
Women + Heart Disease (J Robinson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Women and Heart Disease

Abstract

Women have been under-represented in clinical trials for several decades and a large amount of medical knowledge is based on data in men which are extrapolated to women. Over the past few decades, attempts have been made to increase our understanding of risks and benefits of drugs and devices in women, but the latter have been under-studied. The premarket approval process is used by the FDA to evaluate the safety and effectiveness of high-risk medical devices. The safety and effectiveness of a substantial minority of these devices has been shown to differ by sex. However, pivotal studies of these devices that lead to FDA approval often do not include adequate numbers of women nor do most stratify outcomes by sex. Numerous attempts and initiatives to increase availability of sex-specific data have improved this evidence gap modestly, but additional policy changes are necessary to optimize safety and effectiveness evaluation in women.

Keywords

FDA Device regulation Women 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Sanket Dhruva declares no conflicts of interest. Esme Cullen declares no conflicts of interest. Rita Redberg declares no conflicts of interest.

Dr. Redberg is a current member of the FDA Circulatory System Devices Panel.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Rogers WA, Ballantne AJ. Exclusion of women from clinical research: myth or reality? Mayo Clin Proc. 2008;83:536–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayes SN, Redberg RF. Dispelling the myths: calling for sex-specific reporting of trial results. Mayo Clin Proc. 2008;83:523–5.PubMedCrossRefGoogle Scholar
  3. 3.
    United States General Accounting Office. National Institutes of Health: problems in implementing policy on women in study populations. http://archive.gao.gov/d48t13/141859.pdf. Accessed 2 Apr 2014.
  4. 4.
    Department of Health and Human Services. Office of Device Evaluation annual report for fiscal year 1994. Washington DC: US Department of Health and Human Services; 1994. p 26.Google Scholar
  5. 5.
    Food and Drug Administration. Medical Devices: Premarket Approval. Silver Spring: Food and Drug Administration; 2012. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/default.htm. Accessed 2 Apr 2014.
  6. 6.
    Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Blauwet LA, Hayes SN, McManus D, Redberg RF, Walsh MN. Low rate of sex-specific result reporting in cardiovascular trials. Mayo Clin Proc. 2007;82:166–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Kim ES, Menon V. Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol. 2009;29:279–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009;2679–85.Google Scholar
  10. 10.••
    Dhruva SS, Bero LA, Redberg RF. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011;4:165–71. This study describes the current state of available data for cardiovascular devices in women at the time of approval.PubMedCrossRefGoogle Scholar
  11. 11.
    Food and Drug Administration. Summary of safety and effectiveness. PMA 000009: Phylax AV ICD with Programmer Software (I-GAV.2.U). Food and Drug Administration, Center for Devices and Radiological Health, Office of Device Evaluation; 2000. http://www.accessdata.fda.gov/cdrh_docs/pdf/P000009b.pdf. Accessed 2 Apr 2014.
  12. 12.
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.PubMedCrossRefGoogle Scholar
  13. 13.
    Redberg RF. Is what is good for the gander really good for the goose? Arch Intern Med. 2009;169:1460–1.PubMedCrossRefGoogle Scholar
  14. 14.
    Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, Machado C. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169:1500–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Peterson PN, Daugherty SL, Wang Y, Vidaillet JH, Heidenreich PA, Curtis JP, et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation. 2009;119:1078–84.PubMedCrossRefGoogle Scholar
  16. 16.
    MacFadden DR, Crystal E, Krahn AD, Mangat I, Healey JS, Dorian P, et al. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database. Ann Intern Med. 2012;156:195–203.PubMedCrossRefGoogle Scholar
  17. 17.
    Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) Trial. J Am Coll Cardiol. 2011;57:813–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Dhruva SS, Redberg RF. The need for sex-specific data prior to Food and Drug Administration approval. J Am Coll Cardiol. 2010;55:261.PubMedCrossRefGoogle Scholar
  19. 19.
    Dhruva SS, Redberg RF. Sex-specific outcomes for HeartMate II. J Am Coll Cardiol. 2011;58:1285.PubMedCrossRefGoogle Scholar
  20. 20.
    Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, et al. Preoperative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014;63:880–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Institute of Medicine. Women's health research: progress, pitfalls, and promise. Washington, DC: National Academies Press; 2010.Google Scholar
  23. 23.••
    Food and Drug Administration. Draft guidance for industry and Food and Drug Administration staff – evaluation of sex differences in medical device clinical studies. Silver Spring: Food and Drug Administration; 2011. This is the FDA’s draft guidance and provides guidelines for effectively evaluating medical devices in women.Google Scholar
  24. 24.
    Dhruva SS, Redberg RF. Evaluating sex differences in medical device clinical trials: time for action. JAMA. 2012;307:1145–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Sanket S. Dhruva
    • 1
  • Esme B. Cullen
    • 2
  • Rita F. Redberg
    • 3
    Email author
  1. 1.Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of California, DavisSacramentoUSA
  2. 2.School of MedicineUniversity of California, San FranciscoSan FranciscoUSA
  3. 3.Division of Cardiology, Department of MedicineUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations